Evotec SE EVOTF Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0001104659-25-035638
cik 1412558
name EVOTEC SE
sic 2834
countryba DE
stprba
cityba HAMBURG
zipba 22419
bas1 ESSENER BOGEN 7
bas2
baph 49-40-560-810
countryma DE
stprma
cityma HAMBURG
zipma 22419
mas1 ESSENER BOGEN 7
mas2
countryinc DE
stprinc
ein 000000000
former EVOTEC AG
changed 20070917
afs 1-LAF
wksi 0
fye 1231
form 20-F
period 20241231
fy 2024
fp FY
filed 20250417
accepted 2025-04-17 06:06:00.0
prevrpt 0
detail 1
instance evo-20241231x20f_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001104659-25-035638 20221231 Adjustments For Income Tax Expense 21698000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Basic Earnings Loss Per Share -0.9900 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Cash And Cash Equivalents 510909000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Cash Flows From Used In Financing Activities -161421000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Comprehensive Income -200419000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Comprehensive Income -175655000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001104659-25-035638 20231231 Comprehensive Income -1760000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001104659-25-035638 20241231 Comprehensive Income -172785000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Acquisition Of Investments In Associated Companies Other Long Term Investments And Convertibles 15083000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Adjustments For Fair Value Gains Losses 9143000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 5011000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Adjustments For Sharebased Payments 9919000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Adjustments For Share Of Result And Revaluation Of Investments Accounted For Using Equity Method -4312000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20221231 Adjustments For Transactions Costs And Income Related To Acquisitions 4908000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Assets 40328000.0000 EUR 0 ifrs/2024 Classes Of Financial Assets= Equity Instruments And Other Financial Assets; Levels Of Fair Value Hierarchy= Level3 Of Fair Value Hierarchy;
0001104659-25-035638 20241231 Cash Flows From Used In Investing Activities -71187000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Comprehensive Income -598000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001104659-25-035638 20231231 Comprehensive Income -83913000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001104659-25-035638 20241231 Cost Of Sales 173068000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20231231 Current Assets 903162000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Current Contract Assets 30516000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Current Liabilities 2902000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20241231 Current Liabilities 344585000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Current Prepayments And Other Current Assets 45519000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Current Provisions 1572000.0000 EUR 0 ifrs/2024 Classes Of Provision= Provisions For Pensions;
0001104659-25-035638 20211231 Equity 1430136000.0000 EUR 0 ifrs/2024 Components Of Equity= Additional Paidin Capital;
0001104659-25-035638 20211231 Equity -216421000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001104659-25-035638 20221231 Equity 1187184000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Equity 1119908000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Equity 177553000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001104659-25-035638 20231231 Expense Of Restructuring Activities 0.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Gain Recognised In Bargain Purchase Transaction 4908000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Gains Losses On Financial Assets At Fair Value Through Profit Or Loss -9143000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Gains Losses On Financial Assets At Fair Value Through Profit Or Loss -38513000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Gross Profit 175051000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Gross Profit -5252000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20231231 Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill 5011000.0000 EUR 4 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment;
0001104659-25-035638 20241231 Income Taxes Paid Refund Classified As Operating Activities -76083000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Income Tax Expense Continuing Operations 3320000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 95110000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Increase Decrease Through Exercise Of Options 345000.0000 EUR 4 ifrs/2024 Components Of Equity= Issued Capital;
0001104659-25-035638 20241231 Increase Decrease Through Sharebased Payment Transactions 5034000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Intangible Assets And Goodwill 291089000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Interest Paid Classified As Financing Activities 5920000.0000 EUR 4 ifrs/2024 Liabilities Arising From Financing Activities= Loan Liabilities;
0001104659-25-035638 20241231 Inventories -2043000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment;
0001104659-25-035638 20241231 Issued Capital 177553000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Noncurrent Assets 9047000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Dark Blue Therapeutics Ltd Oxford Uk;
0001104659-25-035638 20231231 Noncurrent Provisions 1913000.0000 EUR 0 ifrs/2024 Classes Of Provision= Other Provision;
0001104659-25-035638 20211231 Number Of Shares Issued 176608000.0000 shares 0 ifrs/2024
0001104659-25-035638 20221231 Other Finance Cost 13150000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Other Income 2899000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20231231 Other Operating Expenses 4841000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20241231 Payments For Debt Issue Costs 3795000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Proceeds From Borrowings Classified As Financing Activities 219923000.0000 EUR 4 ifrs/2024 Liabilities Arising From Financing Activities= Loan Liabilities;
0001104659-25-035638 20231231 Profit Loss -10667000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Autobahn Labs Palo Alto Usa;
0001104659-25-035638 20231231 Profit Loss From Operating Activities -39385000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20241231 Profit Loss From Operating Activities -126170000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets -55779000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets -210195000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 222734000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 50113000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets -170713000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 274335000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 225645000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Construction In Progress; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 255853000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 174463000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 1565000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 4304000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 1206000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Purchase Of Intangible Assets Classified As Investing Activities 2677000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Purchase Of Intangible Assets Classified As Investing Activities 14769000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Repayments Of Borrowings Classified As Financing Activities 112880000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Research And Development Expense 7000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20241231 Retained Earnings -672370000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Revenue 796967000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Trade And Other Current Receivables -526000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Credit Impairment Of Financial Instruments= Financial Instruments Not Creditimpaired; Type Of Measurement Of Expected Credit Losses= Lifetime Expected Credit Losses;
0001104659-25-035638 20221231 Weighted Average Shares 176674341.0000 shares 4 ifrs/2024
0001104659-25-035638 20241231 Current Assets 1121000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20231231 Current Contract Liabilities 97587000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Current Investments 90413000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Current Liabilities 1087000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Dark Blue Therapeutics Ltd Oxford Uk;
0001104659-25-035638 20241231 Current Liabilities 981000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Dark Blue Therapeutics Ltd Oxford Uk;
0001104659-25-035638 20241231 Current Liabilities 548000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Topas Therapeutics Gmbh Hamburg Germany;
0001104659-25-035638 20231231 Diluted Earnings Loss Per Share -0.4700 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Equity 1440010000.0000 EUR 0 ifrs/2024 Components Of Equity= Additional Paidin Capital;
0001104659-25-035638 20221231 Equity -392377000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001104659-25-035638 20231231 Equity -476290000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001104659-25-035638 20241231 Equity 952525000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Equity -672370000.0000 EUR 0 ifrs/2024 Components Of Equity= Retained Earnings;
0001104659-25-035638 20241231 Expense Of Restructuring Activities 54930000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Gross Profit 13553000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20231231 Ifrs Other Non Operating Income Expense -714000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20241231 Income Tax Expense Continuing Operations 2102000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss 316000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Increase Decrease Through Sharebased Payment Transactions 9919000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Increase Decrease Through Sharebased Payment Transactions 9630000.0000 EUR 4 ifrs/2024 Components Of Equity= Additional Paidin Capital;
0001104659-25-035638 20221231 Interest Received Classified As Investing Activities 3026000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Interest Received Classified As Investing Activities 10365000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Investment Accounted For Using Equity Method 892000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20241231 Net Deferred Tax Assets 17333000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Net Deferred Tax Liabilities 18137000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Noncurrent Assets 1349306000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Noncurrent Assets 421000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Curexsys Gmbh Gttingen Germany;
0001104659-25-035638 20231231 Noncurrent Liabilities 483000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20231231 Number Of Shares Issued 177185736.0000 shares 0 ifrs/2024 Components Of Equity= Issued Capital;
0001104659-25-035638 20231231 Other Comprehensive Income -1760000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001104659-25-035638 20241231 Other Comprehensive Income Before Tax Financial Assets Measured At Fair Value Through Other Comprehensive Income 2148000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Other Current Financial Assets 4290000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Other Finance Cost 11739000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Other Finance Income 2435000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Other Noncurrent Nonfinancial Assets 837000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Other Noncurrent Nonfinancial Assets 3464000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Other Operating Expenses 2192000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20221231 Payments Of Lease Liabilities Classified As Financing Activities 19046000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Proceeds From Borrowings Classified As Financing Activities 219923000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Proceeds From Exercise Of Options 219000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Proceeds From Issuing Shares 355000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities 2000000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Profit Loss -167000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Eir Biotherapies S.r.l. Mirandola Mo Italy;
0001104659-25-035638 20231231 Profit Loss Before Tax -80593000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Profit Loss From Operating Activities -47507000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets -31110000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 116381000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Construction In Progress; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 692069000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 228741000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 629546000.0000 EUR 0 ifrs/2024 Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets -87464000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 135160000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 686438000.0000 EUR 0 ifrs/2024 Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Repayments Of Borrowings Classified As Financing Activities 24124000.0000 EUR 4 ifrs/2024 Liabilities Arising From Financing Activities= Lease Liabilities;
0001104659-25-035638 20231231 Revenue 781426000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Revenue 611394000.0000 EUR 4 ifrs/2024 Segments= Shared R D;
0001104659-25-035638 20221231 Selling General And Administrative Expense 135071000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period 233083.0000 shares 4 0001104659-25-035638 Components Of Equity= Issued Capital;
0001104659-25-035638 20221231 Total Operating Income And Expenses -17786000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20231231 Trade And Other Current Payables 134319000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Trade And Other Current Receivables -6453000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment;
0001104659-25-035638 20231231 Trade And Other Current Receivables -5636000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Past Due Status= Later Than Four Months;
0001104659-25-035638 20231231 Trade And Other Current Receivables 57742000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Past Due Status= Current;
0001104659-25-035638 20231231 Weighted Average Shares 176916663.0000 shares 4 ifrs/2024
0001104659-25-035638 20231231 Accumulated Other Comprehensive Income -30643000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Acquisition Of Short Term Investments 48391000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Adjustments For Depreciation And Amortisation Expense 92979000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 12195000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Assets 53875000.0000 EUR 0 ifrs/2024 Classes Of Financial Assets= Equity Instruments And Other Financial Assets; Levels Of Fair Value Hierarchy= Level3 Of Fair Value Hierarchy;
0001104659-25-035638 20231231 Assets 2252468000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities -2088000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Comprehensive Income 8519000.0000 EUR 4 ifrs/2024 Components Of Equity= Revaluation Surplus;
0001104659-25-035638 20241231 Comprehensive Income 23127000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001104659-25-035638 20221231 Cost Of Sales 577383000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Current Assets 1071000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Curexsys Gmbh Gttingen Germany;
0001104659-25-035638 20231231 Current Assets 613000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20241231 Current Assets 634000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Eir Biotherapies S.r.l. Mirandola Mo Italy;
0001104659-25-035638 20241231 Current Contract Assets 0.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment;
0001104659-25-035638 20221231 Current Contract Liabilities 122921000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Current Contract Liabilities 106599000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Current Contract Liabilities 57862000.0000 EUR 0 ifrs/2024 Major Customers= Largest Customer;
0001104659-25-035638 20231231 Current Liabilities 464573000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Current Liabilities 148000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Curexsys Gmbh Gttingen Germany;
0001104659-25-035638 20241231 Current Liabilities 187000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Eir Biotherapies S.r.l. Mirandola Mo Italy;
0001104659-25-035638 20241231 Current Provisions 62219000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Current Provisions 19473000.0000 EUR 0 ifrs/2024 Classes Of Provision= Restructuring Provision;
0001104659-25-035638 20241231 Diluted Earnings Loss Per Share -1.1100 EUR 4 ifrs/2024
0001104659-25-035638 20211231 Equity 3053000.0000 EUR 0 ifrs/2024 Components Of Equity= Revaluation Surplus;
0001104659-25-035638 20221231 Equity -21113000.0000 EUR 0 ifrs/2024 Components Of Equity= Revaluation Surplus;
0001104659-25-035638 20241231 Equity 5078000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001104659-25-035638 20221231 Gross Profit 174065000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Ifrs Other Non Operating Income Expense 12357000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill 5011000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Income Taxes Refund Classified As Operating Activities 16434000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Income Tax Expense Continuing Operations 21698000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes -214388000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Increase Decrease In Working Capital -105285000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Increase Decrease Through Exercise Of Options 368000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Interest Paid Classified As Financing Activities 5920000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Investment Accounted For Using Equity Method 2325000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Tucana Biosciences Inc. Boston Usa;
0001104659-25-035638 20241231 Investment Accounted For Using Equity Method 2138000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Noncurrent Liabilities 667987000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Noncurrent Provisions 11985000.0000 EUR 0 ifrs/2024 Classes Of Provision= Provisions For Pensions;
0001104659-25-035638 20241231 Noncurrent Provisions 2918000.0000 EUR 0 ifrs/2024 Classes Of Provision= Other Provision;
0001104659-25-035638 20231231 Number Of Shares Issued 177186000.0000 shares 0 ifrs/2024
0001104659-25-035638 20221231 Other Comprehensive Income -24166000.0000 EUR 4 ifrs/2024 Components Of Equity= Revaluation Surplus;
0001104659-25-035638 20241231 Other Comprehensive Income 23127000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001104659-25-035638 20231231 Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments -1080000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Payments Of Lease Liabilities Classified As Financing Activities 24124000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Proceeds From Exercise Of Options 368000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Profit Loss -3448000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Centauri Therapeutics Gmbh;
0001104659-25-035638 20241231 Profit Loss -3115000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Dark Blue Therapeutics Ltd Oxford Uk;
0001104659-25-035638 20241231 Profit Loss -9418000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Topas Therapeutics Gmbh Hamburg Germany;
0001104659-25-035638 20221231 Profit Loss Before Tax -153957000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Profit Loss From Operating Activities -8122000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20241231 Profit Loss From Operating Activities -142522000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Profit Loss From Operating Activities -16353000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets -3902000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 481874000.0000 EUR 0 ifrs/2024 Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets -75390000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets -78836000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 61763000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 225645000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Construction In Progress; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 20365000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 89484000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 1833000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 1072830000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 241056000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Purchase Of Property Plant And Equipment Classified As Investing Activities 213321000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Repayments Of Borrowings Classified As Financing Activities 112880000.0000 EUR 4 ifrs/2024 Liabilities Arising From Financing Activities= Loan Liabilities;
0001104659-25-035638 20221231 Revenue 702020000.0000 EUR 4 ifrs/2024 Segments= Shared R D;
0001104659-25-035638 20231231 Revenue 672977000.0000 EUR 4 ifrs/2024 Segments= Shared R D;
0001104659-25-035638 20231231 Revenue 597000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Centauri Therapeutics Gmbh;
0001104659-25-035638 20231231 Selling General And Administrative Expense 26442000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20241231 Selling General And Administrative Expense 188201000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period 367720.0000 shares 4 0001104659-25-035638 Components Of Equity= Issued Capital;
0001104659-25-035638 20231231 Share Issue Related Cost -14000.0000 EUR 4 ifrs/2024 Components Of Equity= Additional Paidin Capital;
0001104659-25-035638 20231231 Share Of Profit Loss And Reevaluation Of Associates And Joint Ventures Accounted For Using Equity Method -20752000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20241231 Total Operating Income And Expenses -29906000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20231231 Trade And Other Current Receivables -170000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Past Due Status= Not Later Than One Month;
0001104659-25-035638 20241231 Trade And Other Current Receivables -161000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Past Due Status= Current;
0001104659-25-035638 20221231 Adjustments For Depreciation And Amortisation Expense 83196000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Adjustments For Fair Value Gains Losses 39546000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Adjustments For Income Tax Expense 3320000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Adjustments For Income Tax Expense 2102000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Adjustments For Share Of Result And Revaluation Of Investments Accounted For Using Equity Method -20752000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20241231 Assets 1912502000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Assets 22503000.0000 EUR 0 ifrs/2024 Classes Of Financial Assets= Equity Instruments And Other Financial Assets; Levels Of Fair Value Hierarchy= Level3 Of Fair Value Hierarchy;
0001104659-25-035638 20241231 Basic Earnings Loss Per Share -1.1100 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Cash And Cash Equivalents 306387000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Cash Flows From Used In Financing Activities -58145000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Cash Flows From Used In Operating Activities 36439000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Cash Flows From Used In Operating Activities 18220000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Current Assets 7560000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Topas Therapeutics Gmbh Hamburg Germany;
0001104659-25-035638 20231231 Current Contract Assets 25000000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Current Provisions 45165000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Current Tax Liabilities Current 8517000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20211231 Equity 176608000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001104659-25-035638 20241231 Equity 1454688000.0000 EUR 0 ifrs/2024 Components Of Equity= Additional Paidin Capital;
0001104659-25-035638 20241231 Equity And Liabilities 1912502000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Income Taxes Paid Refund Classified As Operating Activities 18500000.0000 EUR 4 ifrs/2024 incl. 62,233k (2023: 12,609k; 2022: 16,434k) of R&D tax credits received
0001104659-25-035638 20231231 Income Taxes Paid Refund Classified As Operating Activities 12902000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Increase Decrease Through Exercise Of Options 233000.0000 EUR 4 ifrs/2024 Components Of Equity= Issued Capital;
0001104659-25-035638 20241231 Increase Decrease Through Sharebased Payment Transactions 5034000.0000 EUR 4 ifrs/2024 Components Of Equity= Additional Paidin Capital;
0001104659-25-035638 20231231 Interest Paid Classified As Financing Activities 12853000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Interest Paid Classified As Financing Activities 12853000.0000 EUR 4 ifrs/2024 Liabilities Arising From Financing Activities= Loan Liabilities;
0001104659-25-035638 20221231 Investment Accounted For Using Equity Method 3954000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Aggregated Individually Immaterial Associates Prior Year;
0001104659-25-035638 20221231 Investment Accounted For Using Equity Method 4022000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Dark Blue Therapeutics Ltd Oxford Uk;
0001104659-25-035638 20241231 Investment Accounted For Using Equity Method 2000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Aggregated Individually Immaterial Associates;
0001104659-25-035638 20231231 Noncurrent Assets 727000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Autobahn Labs Palo Alto Usa;
0001104659-25-035638 20231231 Noncurrent Assets 248000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Dark Blue Therapeutics Ltd Oxford Uk;
0001104659-25-035638 20241231 Noncurrent Contract Liabilities 156679000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Noncurrent Liabilities 9098000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Dark Blue Therapeutics Ltd Oxford Uk;
0001104659-25-035638 20241231 Noncurrent Liabilities 615392000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Noncurrent Provisions 16063000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Noncurrent Provisions 10223000.0000 EUR 0 ifrs/2024 Classes Of Provision= Provisions For Pensions;
0001104659-25-035638 20241231 Number Of Shares Issued 177553456.0000 shares 0 ifrs/2024 Components Of Equity= Issued Capital;
0001104659-25-035638 20221231 Other Adjustments For Noncash Items -16017000.0000 EUR 4 ifrs/2024 Constitutes derivative revaluations, lease disposals, and allowances for doubtful accounts
0001104659-25-035638 20241231 Other Adjustments For Noncash Items 23702000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Other Comprehensive Income -24764000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Other Comprehensive Income Before Tax Exchange Differences On Translation -1760000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Other Comprehensive Income Before Tax Financial Assets Measured At Fair Value Through Other Comprehensive Income -13500000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Other Current Nonfinancial Liabilities 27446000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Other Finance Income 8336000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Other Income 3340000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20241231 Other Income 49802000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20241231 Proceeds From Borrowings Classified As Financing Activities 900000.0000 EUR 4 ifrs/2024 Liabilities Arising From Financing Activities= Loan Liabilities;
0001104659-25-035638 20250228 Proceeds From Borrowings Classified As Financing Activities 43961000.0000 EUR 0 ifrs/2024 Borrowings By Name= Facility With European Investment Bank; Nonadjusting Events After Reporting Period= Borrowing Draw Down;
0001104659-25-035638 20221231 Profit Loss -175655000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001104659-25-035638 20241231 Profit Loss -196078000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Profit Loss -4483000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Centauri Therapeutics Gmbh;
0001104659-25-035638 20241231 Profit Loss -3974000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets -41397000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 249853000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 901020000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 823937000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets -700000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets -91262000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 323066000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 252254000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Construction In Progress; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 228761000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Research And Development Expense 50857000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Research And Development Expense -865000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Elimination Of Intersegment Amounts;
0001104659-25-035638 20241231 Revenue 1294000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20231231 Share Issue Related Cost -14000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Total Operating Income And Expenses -222558000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Trade And Other Current Receivables -6121000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Credit Impairment Of Financial Instruments= Financial Instruments Creditimpaired;
0001104659-25-035638 20231231 Trade And Other Current Receivables -331000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Credit Impairment Of Financial Instruments= Financial Instruments Not Creditimpaired; Type Of Measurement Of Expected Credit Losses= Lifetime Expected Credit Losses;
0001104659-25-035638 20241231 Trade And Other Current Receivables 116319000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Trade And Other Current Receivables -11141000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment;
0001104659-25-035638 20241231 Trade And Other Current Receivables 9473000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Past Due Status= Later Than One Month And Not Later Than Four Months;
0001104659-25-035638 20241231 Weighted Average Shares 177295234.0000 shares 4 ifrs/2024
0001104659-25-035638 20241231 Adjustments For Depreciation And Amortisation Expense 101618000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Adjustments For Finance Income Cost -13536000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Cash And Cash Equivalents 415155000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241130 Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities 1.0000 EUR 0 ifrs/2024 Significant Investments In Subsidiaries= Evotec Drug Substance Germany Halle Germany;
0001104659-25-035638 20231231 Current Assets 9451000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Centauri Therapeutics Gmbh;
0001104659-25-035638 20241231 Current Contract Assets 46034000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Current Contract Liabilities 49153000.0000 EUR 0 ifrs/2024 Major Customers= Largest Customer;
0001104659-25-035638 20231231 Current Deferred Income Other Than Current Contract Liabilities 10268000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Current Deferred Income Other Than Current Contract Liabilities 3216000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Current Investments 93203000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Current Provisions 2184000.0000 EUR 0 ifrs/2024 Classes Of Provision= Provisions For Pensions;
0001104659-25-035638 20241231 Current Provisions 31317000.0000 EUR 0 ifrs/2024 Classes Of Provision= Provisions For Other Personnel Expenses;
0001104659-25-035638 20231231 Current Tax Liabilities Current 5565000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Effect Of Exchange Rate Changes On Cash And Cash Equivalents -19040000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Effect Of Exchange Rate Changes On Cash And Cash Equivalents 9866000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Equity 176953000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001104659-25-035638 20231231 Equity And Liabilities 2252468000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Expense Of Restructuring Activities 751000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20241231 Gross Profit 114881000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Gross Profit 102192000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20241231 Income Taxes Refund Classified As Operating Activities 62233000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Income Tax Relating To Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss -2193000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes -265131000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Increase Decrease Through Exercise Of Options 345000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Increase Decrease Through Exercise Of Options 233000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Increase Decrease Through Sharebased Payment Transactions 9630000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Interest Paid Classified As Financing Activities 5731000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Investment Accounted For Using Equity Method 3071000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Noncurrent Assets 549000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20241231 Non Current Investments And Other Non Current Financial Assets 40014000.0000 EUR 0 0001104659-25-035638
0001104659-25-035638 20241231 Number Of Shares Issued 177553456.0000 shares 0 ifrs/2024
0001104659-25-035638 20241231 Other Comprehensive Income Before Tax Exchange Differences On Translation 23127000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Other Comprehensive Income Before Tax Financial Assets Measured At Fair Value Through Other Comprehensive Income 10056000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Other Current Financial Assets 12759000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Other Current Nonfinancial Liabilities 22572000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Other Finance Cost 11699000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Other Income 62524000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Other Operating Expenses 44202000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20241231 Proceeds From Sale Of Short Term Investment 35667000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 19003000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 585000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 806563000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets -59365000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets -2686000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 1749000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20221231 Acquisition Of Short Term Investments 355817000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 4251000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Purchase Of Property Plant And Equipment Classified As Investing Activities 117468000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Repayments Of Borrowings Classified As Financing Activities 22446000.0000 EUR 4 ifrs/2024 Liabilities Arising From Financing Activities= Lease Liabilities;
0001104659-25-035638 20241231 Repayments Of Borrowings Classified As Financing Activities 128849000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Revenue 108449000.0000 EUR 4 ifrs/2024 Segments= Just Evotec Biologics;
0001104659-25-035638 20241231 Revenue -1208000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Elimination Of Intersegment Amounts;
0001104659-25-035638 20241231 Revenue -1049000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Elimination Of Intersegment Amounts; Segments= Just Evotec Biologics;
0001104659-25-035638 20221231 Selling General And Administrative Expense 156190000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Selling General And Administrative Expense 158915000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20221231 Share Issue Related Cost 45000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Total Operating Income And Expenses -153215000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20221231 Total Operating Income And Expenses -135429000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Total Operating Income And Expenses -188425000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Trade And Other Current Receivables -367000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Past Due Status= Current;
0001104659-25-035638 20231231 Trade And Other Current Receivables -280000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Past Due Status= Later Than One Month And Not Later Than Four Months;
0001104659-25-035638 20241231 Trade And Other Current Receivables 16903000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Past Due Status= Later Than Four Months;
0001104659-25-035638 20241231 Adjustments For Gain Loss On Disposal Of Investments In Subsidiaries Joint Ventures And Associates -8648000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Adjustments For Sharebased Payments 9630000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Adjustments For Sharebased Payments 5035000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Adjustments For Share Of Result And Revaluation Of Investments Accounted For Using Equity Method -15098000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Cash Flows From Used In Financing Activities 71963000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Cost Of Sales 94679000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20231231 Cost Of Sales 113701000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20231231 Cost Of Sales 492674000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20241231 Current Assets 291000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Dark Blue Therapeutics Ltd Oxford Uk;
0001104659-25-035638 20231231 Current Contract Assets 0.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment;
0001104659-25-035638 20241231 Current Liabilities 245000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Centauri Therapeutics Gmbh;
0001104659-25-035638 20241231 Current Provisions 9858000.0000 EUR 0 ifrs/2024 Classes Of Provision= Other Provision;
0001104659-25-035638 20231231 Current Restricted Cash And Cash Equivalents 11819000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Current Tax Assets Noncurrent 34357000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Deferred And Current Tax On Future Deductible Expenses -301000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20221231 Deferred And Current Tax On Future Deductible Expenses -301000.0000 EUR 4 0001104659-25-035638 Components Of Equity= Retained Earnings;
0001104659-25-035638 20211231 Equity 1377685000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20211231 Equity -15691000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001104659-25-035638 20231231 Equity 177186000.0000 EUR 0 ifrs/2024 Components Of Equity= Issued Capital;
0001104659-25-035638 20231231 Equity -12594000.0000 EUR 0 ifrs/2024 Components Of Equity= Revaluation Surplus;
0001104659-25-035638 20221231 Expense Of Restructuring Activities 0.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Gains Losses On Financial Assets At Fair Value Through Profit Or Loss -172159000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Gross Profit -45252000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20241231 Ifrs Other Non Operating Income Expense 636000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Income Taxes Refund Classified As Operating Activities 12609000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Income Tax Relating To Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss 419000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Inventories 30890000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Investment Accounted For Using Equity Method 1371000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Autobahn Labs Palo Alto Usa;
0001104659-25-035638 20221231 Investment Accounted For Using Equity Method 405000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Topas Therapeutics Gmbh Hamburg Germany;
0001104659-25-035638 20231231 Investment Accounted For Using Equity Method 892000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Aggregated Individually Immaterial Associates Prior Year;
0001104659-25-035638 20231231 Investment Accounted For Using Equity Method 2179000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Centauri Therapeutics Gmbh;
0001104659-25-035638 20241231 Investment Accounted For Using Equity Method 1264000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Centauri Therapeutics Gmbh;
0001104659-25-035638 20231231 Issued Capital 177186000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Net Deferred Tax Assets 14330000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Net Deferred Tax Liabilities 14516000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Noncurrent Assets 299000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Centauri Therapeutics Gmbh;
0001104659-25-035638 20241231 Noncurrent Assets 1752000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Eir Biotherapies S.r.l. Mirandola Mo Italy;
0001104659-25-035638 20221231 Noncurrent Contract Liabilities 206136000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Non Current Investments And Other Non Current Financial Assets 139023000.0000 EUR 0 0001104659-25-035638
0001104659-25-035638 20241231 Noncurrent Liabilities 4325000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20231231 Noncurrent Provisions 2164000.0000 EUR 0 ifrs/2024 Classes Of Provision= Provisions For Other Personnel Expenses;
0001104659-25-035638 20241231 Noncurrent Provisions 5128000.0000 EUR 0 ifrs/2024 Classes Of Provision= Restructuring Provision;
0001104659-25-035638 20211231 Number Of Shares Issued 176608195.0000 shares 0 ifrs/2024 Components Of Equity= Issued Capital;
0001104659-25-035638 20221231 Number Of Shares Issued 176953000.0000 shares 0 ifrs/2024
0001104659-25-035638 20231231 Other Comprehensive Income 6759000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Other Comprehensive Income 23294000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Other Comprehensive Income Before Tax Gains Losses On Remeasurements Of Defined Benefit Plans 1217000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Other Income 64793000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Other Income 52700000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Other Operating Expenses 39361000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20241231 Other Operating Expenses 16116000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20241231 Proceeds From Borrowings Classified As Financing Activities 900000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Proceeds From Divestment Sale Of Investments In Associated Companies Other Long Term Investments And Convertibles 1396000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Proceeds From Sale Of Short Term Investment 260363000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20221231 Profit Loss -175655000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Profit Loss -83913000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001104659-25-035638 20241231 Profit Loss -196078000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets -42680000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets -136405000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 240328000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 1318000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 197648000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 166955000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 116381000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Construction In Progress; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 787000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets -271474000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 168565000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets -66790000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets -237591000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets -3098000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 222624000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 408025000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 252254000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Construction In Progress; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 1133000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Research And Development Expense 576000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20241231 Research And Development Expense 51146000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Retained Earnings -476290000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Revenue 49428000.0000 EUR 4 ifrs/2024 Segments= Just Evotec Biologics;
0001104659-25-035638 20231231 Revenue 2353000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20241231 Revenue 185573000.0000 EUR 4 ifrs/2024 Segments= Just Evotec Biologics;
0001104659-25-035638 20231231 Selling General And Administrative Expense 143167000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20221231 Share Issue Related Cost 45000.0000 EUR 4 ifrs/2024 Components Of Equity= Additional Paidin Capital;
0001104659-25-035638 20221231 Share Of Profit Loss And Reevaluation Of Associates And Joint Ventures Accounted For Using Equity Method -15098000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20241231 Total Operating Income And Expenses 865000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Elimination Of Intersegment Amounts;
0001104659-25-035638 20241231 Trade And Other Current Payables 85792000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Trade And Other Current Receivables 98396000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Trade And Other Current Receivables 12688000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Past Due Status= Later Than One Month And Not Later Than Four Months;
0001104659-25-035638 20241231 Trade And Other Current Receivables -10905000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Past Due Status= Later Than Four Months;
0001104659-25-035638 20241231 Trade And Other Current Receivables 87986000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Past Due Status= Current;
0001104659-25-035638 20241231 Trade And Other Current Receivables 13098000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Past Due Status= Not Later Than One Month;
0001104659-25-035638 20221231 Acquisition Of Investments In Associated Companies Other Long Term Investments And Convertibles 62959000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Acquisition Of Investments In Associated Companies Other Long Term Investments And Convertibles 23644000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20221231 Adjustments For Fair Value Gains Losses 172159000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Adjustments For Finance Income Cost -2475000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Adjustments For Finance Income Cost -9264000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20211231 Cash And Cash Equivalents 699326000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities -11503000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Cash Flows From Used In Investing Activities -13291000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Cash Flows From Used In Operating Activities 205811000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities 20859000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Comprehensive Income -196078000.0000 EUR 4 ifrs/2024 Components Of Equity= Retained Earnings;
0001104659-25-035638 20221231 Cost Of Sales 482704000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Cost Of Sales 606375000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Cost Of Sales 509361000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Current Assets 4321000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Dark Blue Therapeutics Ltd Oxford Uk;
0001104659-25-035638 20241231 Current Assets 681964000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Current Financial Liabilities 50795000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Current Liabilities 2257000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Autobahn Labs Palo Alto Usa;
0001104659-25-035638 20241231 Current Liabilities 2072000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20231231 Current Prepayments And Other Current Assets 51345000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Current Provisions 1491000.0000 EUR 0 ifrs/2024 Classes Of Provision= Other Provision;
0001104659-25-035638 20241231 Current Restricted Cash And Cash Equivalents 12931000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Current Tax Assets Current 41879000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Diluted Earnings Loss Per Share -0.9900 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Equity 1449654000.0000 EUR 0 ifrs/2024 Components Of Equity= Additional Paidin Capital;
0001104659-25-035638 20231231 Equity -18049000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001104659-25-035638 20241231 Equity -12427000.0000 EUR 0 ifrs/2024 Components Of Equity= Revaluation Surplus;
0001104659-25-035638 20241231 Expense Of Restructuring Activities 54179000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20241231 Gross Profit -865000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Elimination Of Intersegment Amounts;
0001104659-25-035638 20231231 Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss -13000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Increase Decrease In Working Capital 9944000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Increase Decrease Through Exercise Of Options 368000.0000 EUR 4 ifrs/2024 Components Of Equity= Issued Capital;
0001104659-25-035638 20221231 Increase Decrease Through Sharebased Payment Transactions 9919000.0000 EUR 4 ifrs/2024 Components Of Equity= Additional Paidin Capital;
0001104659-25-035638 20241231 Inventories 31122000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Investment Accounted For Using Equity Method 3967000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Curexsys Gmbh Gttingen Germany;
0001104659-25-035638 20241231 Investment Accounted For Using Equity Method 873000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Eir Biotherapies S.r.l. Mirandola Mo Italy;
0001104659-25-035638 20231231 Noncurrent Assets 5072000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20241231 Noncurrent Assets 1230538000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Noncurrent Assets 972000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Topas Therapeutics Gmbh Hamburg Germany;
0001104659-25-035638 20231231 Noncurrent Contract Liabilities 155287000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Noncurrent Financial Liabilities 477112000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Noncurrent Financial Liabilities 392743000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Number Of Shares Issued 176952653.0000 shares 0 ifrs/2024 Components Of Equity= Issued Capital;
0001104659-25-035638 20221231 Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments -11729000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Other Comprehensive Income Before Tax Gains Losses On Remeasurements Of Defined Benefit Plans -51000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Other Income 81582000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Other Noncurrent Nonfinancial Liabilities 1387000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20221231 Other Operating Expenses 1965000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20221231 Other Operating Expenses 1965000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20241231 Proceeds From Divestment Sale Of Investments In Associated Companies Other Long Term Investments And Convertibles 69370000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20221231 Proceeds From Exercise Of Options 344000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Proceeds From Sale Of Short Term Investment 205166000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities 530000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Profit Loss -83913000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Profit Loss -890000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Quantro Therapeutics Gmbh Wien Austria;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets -733000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets -60414000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 285246000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 4689000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 148842000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets -760000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 177017000.0000 EUR 0 ifrs/2024 Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets -82011000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets -386392000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Research And Development Expense 68529000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Research And Development Expense 68529000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20221231 Revenue 751448000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Revenue -160000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Elimination Of Intersegment Amounts; Segments= Shared R D;
0001104659-25-035638 20241231 Selling General And Administrative Expense 29286000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20221231 Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period 344458.0000 shares 4 0001104659-25-035638 Components Of Equity= Issued Capital;
0001104659-25-035638 20241231 Share Of Profit Loss And Reevaluation Of Associates And Joint Ventures Accounted For Using Equity Method -4312000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20241231 Total Operating Income And Expenses -228362000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Trade And Other Current Receivables 25837000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Past Due Status= Not Later Than One Month;
0001104659-25-035638 20241231 Trade And Other Current Receivables -10616000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Credit Impairment Of Financial Instruments= Financial Instruments Creditimpaired;
0001104659-25-035638 20241231 Other Comprehensive Income 167000.0000 EUR 4 ifrs/2024 Components Of Equity= Revaluation Surplus;
0001104659-25-035638 20241231 Accumulated Other Comprehensive Income -7347000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Acquisition Of Short Term Investments 29388000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Additional Paidin Capital 1449654000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Additional Paidin Capital 1454688000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Basic Earnings Loss Per Share -0.4700 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Cash Flows From Used In Investing Activities -412797000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Comprehensive Income -24166000.0000 EUR 4 ifrs/2024 Components Of Equity= Revaluation Surplus;
0001104659-25-035638 20231231 Comprehensive Income -77153000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Comprehensive Income 167000.0000 EUR 4 ifrs/2024 Components Of Equity= Revaluation Surplus;
0001104659-25-035638 20241231 Cost Of Sales 682086000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Cost Of Sales -344000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Elimination Of Intersegment Amounts;
0001104659-25-035638 20231231 Current Assets 1272000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Autobahn Labs Palo Alto Usa;
0001104659-25-035638 20241231 Current Assets 383000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Centauri Therapeutics Gmbh;
0001104659-25-035638 20231231 Current Financial Liabilities 149096000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Current Provisions 41490000.0000 EUR 0 ifrs/2024 Classes Of Provision= Provisions For Other Personnel Expenses;
0001104659-25-035638 20231231 Current Tax Assets Current 80659000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Current Tax Assets Noncurrent 94393000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20231231 Effect Of Exchange Rate Changes On Cash And Cash Equivalents 644000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Equity -16289000.0000 EUR 0 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001104659-25-035638 20221231 Gross Profit 219316000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Gross Profit 180303000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill 5011000.0000 EUR 4 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Depreciation Amortisation And Impairment; Classes Of Intangible Assets Other Than Goodwill= Technologybased Intangible Assets;
0001104659-25-035638 20221231 Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss 357000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Increase Decrease In Working Capital 68207000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Intangible Assets And Goodwill 309295000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Interest Received Classified As Investing Activities 5647000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Inventories -2573000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment;
0001104659-25-035638 20221231 Investment Accounted For Using Equity Method 16043000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Noncurrent Deferred Income Other Than Noncurrent Contract Liabilities 30557000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Noncurrent Liabilities 2000.0000 EUR 0 ifrs/2024 Significant Investments In Associates= Eir Biotherapies S.r.l. Mirandola Mo Italy;
0001104659-25-035638 20241231 Noncurrent Provisions 19585000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Noncurrent Provisions 1315000.0000 EUR 0 ifrs/2024 Classes Of Provision= Provisions For Other Personnel Expenses;
0001104659-25-035638 20231231 Other Adjustments For Noncash Items -114000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Other Comprehensive Income -598000.0000 EUR 4 ifrs/2024 Components Of Equity= Reserve Of Exchange Differences On Translation;
0001104659-25-035638 20231231 Other Comprehensive Income 8519000.0000 EUR 4 ifrs/2024 Components Of Equity= Revaluation Surplus;
0001104659-25-035638 20221231 Other Comprehensive Income Before Tax Exchange Differences On Translation -598000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments -5075000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Other Comprehensive Income Before Tax Gains Losses On Remeasurements Of Defined Benefit Plans 1420000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Other Finance Income 9263000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Other Income 78242000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Other Income 2269000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20241231 Other Noncurrent Nonfinancial Liabilities 1312000.0000 EUR 0 ifrs/2024
0001104659-25-035638 20241231 Other Operating Expenses 13924000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20231231 Payments Of Lease Liabilities Classified As Financing Activities 22446000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Proceeds From Government Grants Classified As Investing Activities 4341000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Profit Loss -2176000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Curexsys Gmbh Gttingen Germany;
0001104659-25-035638 20231231 Profit Loss -9210000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Dark Blue Therapeutics Ltd Oxford Uk;
0001104659-25-035638 20241231 Profit Loss Before Tax -193977000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Profit Loss From Operating Activities 20850000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Profit Loss From Operating Activities -63037000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20221231 Profit Loss From Operating Activities 83887000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20221231 Property Plant And Equipment Including Rightofuse Assets 168327000.0000 EUR 0 ifrs/2024 Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 339277000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 214971000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Buildings And Leasehold Improvements; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20231231 Property Plant And Equipment Including Rightofuse Assets 989000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 22694000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Fixtures And Fittings; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 170434000.0000 EUR 0 ifrs/2024 Classes Of Property Plant And Equipment= Plant Machinery And Equipment; Property Plant And Equipment Including Rightofuse Assets= Property Plant And Equipment;
0001104659-25-035638 20241231 Property Plant And Equipment Including Rightofuse Assets 137499000.0000 EUR 0 ifrs/2024 Property Plant And Equipment Including Rightofuse Assets= Rightofuse Assets;
0001104659-25-035638 20221231 Purchase Of Property Plant And Equipment Classified As Investing Activities 181354000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Repayments Of Borrowings Classified As Financing Activities 34067000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20241231 Repayments Of Borrowings Classified As Financing Activities 128849000.0000 EUR 4 ifrs/2024 Liabilities Arising From Financing Activities= Loan Liabilities;
0001104659-25-035638 20221231 Research And Development Expense 76642000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20221231 Research And Development Expense 76635000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Shared R D;
0001104659-25-035638 20241231 Revenue 1000.0000 EUR 4 ifrs/2024 Significant Investments In Associates= Centauri Therapeutics Gmbh;
0001104659-25-035638 20221231 Selling General And Administrative Expense 21119000.0000 EUR 4 ifrs/2024 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20231231 Selling General And Administrative Expense 169610000.0000 EUR 4 ifrs/2024
0001104659-25-035638 20231231 Total Operating Income And Expenses -34133000.0000 EUR 4 0001104659-25-035638 Segment Consolidation Items= Operating Segments; Segments= Just Evotec Biologics;
0001104659-25-035638 20241231 Total Operating Income And Expenses -257403000.0000 EUR 4 0001104659-25-035638
0001104659-25-035638 20231231 Trade And Other Current Receivables 8582000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Gross Carrying Amount; Past Due Status= Later Than Four Months;
0001104659-25-035638 20241231 Trade And Other Current Receivables -32000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Past Due Status= Later Than One Month And Not Later Than Four Months;
0001104659-25-035638 20241231 Trade And Other Current Receivables -43000.0000 EUR 0 ifrs/2024 Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount= Accumulated Impairment; Past Due Status= Not Later Than One Month;

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Other Noncurrent Nonfinancial Liabilities ifrs/2024 0 0 monetary I C Other non-current non-financial liabilities The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]
Accumulated Other Comprehensive Income ifrs/2024 0 0 monetary I C Accumulated other comprehensive income The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]
Current Financial Liabilities ifrs/2024 0 0 monetary I C Current financial liabilities The amount of current financial liabilities. [Refer: Financial liabilities]
Gross Profit ifrs/2024 0 0 monetary D C Gross profit The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]
Income Tax Relating To Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss ifrs/2024 0 0 monetary D D Income tax relating to components of other comprehensive income that will be reclassified to profit or loss The amount of income tax relating to amounts recognised in other comprehensive income that will be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]
Increase Decrease In Working Capital ifrs/2024 0 0 monetary D C Increase (decrease) in working capital The increase (decrease) in working capital.
Number Of Shares Issued ifrs/2024 0 0 shares I Number of shares issued The number of shares issued by the entity.
Other Adjustments For Noncash Items ifrs/2024 0 0 monetary D D Other adjustments for non-cash items Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]
Profit Loss Before Tax ifrs/2024 0 0 monetary D C Profit (loss) before tax The profit (loss) before tax expense or income. [Refer: Profit (loss)]
Purchase Of Property Plant And Equipment Classified As Investing Activities ifrs/2024 0 0 monetary D C Purchase of property, plant and equipment, classified as investing activities The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]
Repayments Of Borrowings Classified As Financing Activities ifrs/2024 0 0 monetary D C Repayments of borrowings, classified as financing activities The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]
Current Investments ifrs/2024 0 0 monetary I D Current investments The amount of current investments.
Adjustments For Transactions Costs And Income Related To Acquisitions 0001104659-25-035638 1 0 monetary D C Adjustments For Transactions Costs And Income Related To Acquisitions Adjustments for transaction costs and income related to acquisitions, to reconcile profit (loss) to net cash flow from (used in) operating activities.
Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes ifrs/2024 0 0 monetary D D Increase (decrease) in cash and cash equivalents before effect of exchange rate changes The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]
Other Comprehensive Income Before Tax Exchange Differences On Translation ifrs/2024 0 0 monetary D C Other comprehensive income, before tax, exchange differences on translation of foreign operations The amount of other comprehensive income, before tax, after reclassification adjustments, related to exchange differences on translation of financial statements of foreign operations. [Refer: Other comprehensive income, before tax]
Other Income ifrs/2024 0 0 monetary D C Other income The amount of operating income that the entity does not separately disclose in the same statement or note.
Retained Earnings ifrs/2024 0 0 monetary I C Retained earnings A component of equity representing the entity's cumulative undistributed earnings or deficit.
Equity And Liabilities ifrs/2024 0 0 monetary I C Equity and liabilities The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]
Ifrs Other Non Operating Income Expense 0001104659-25-035638 1 0 monetary D C IFRS Other Non-Operating Income (Expense) Amount of income (expense) related to nonoperating activities, classified as other.
Inventories ifrs/2024 0 0 monetary I D Current inventories The amount of current inventories. [Refer: Inventories]
Other Finance Cost ifrs/2024 0 0 monetary D D Other finance cost The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]
Proceeds From Issuing Shares ifrs/2024 0 0 monetary D D Proceeds from issuing shares The cash inflow from issuing shares.
Profit Loss From Operating Activities ifrs/2024 0 0 monetary D C Profit (loss) from operating activities The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]
Property Plant And Equipment Including Rightofuse Assets ifrs/2024 0 0 monetary I D Property, plant and equipment including right-of-use assets The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]
Trade And Other Current Payables ifrs/2024 0 0 monetary I C Trade and other current payables The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]
Cash And Cash Equivalents ifrs/2024 0 0 monetary I D Cash and cash equivalents The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]
Other Operating Expenses 0001104659-25-035638 1 0 monetary D D Other Operating Expenses The amount of operating expense that the entity does not separately disclose in the same statement or note.
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period 0001104659-25-035638 1 0 shares D Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Number of share options (or share units) exercised during the current period.
Comprehensive Income ifrs/2024 0 0 monetary D C Comprehensive income The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.
Current Liabilities ifrs/2024 0 0 monetary I C Current liabilities The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.
Current Prepayments And Other Current Assets ifrs/2024 0 0 monetary I D Current prepayments and other current assets The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]
Effect Of Exchange Rate Changes On Cash And Cash Equivalents ifrs/2024 0 0 monetary D D Effect of exchange rate changes on cash and cash equivalents The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]
Gain Recognised In Bargain Purchase Transaction ifrs/2024 0 0 monetary D C Gain recognised in bargain purchase transaction The amount of any gain recognised in a business combination in which the net of the identifiable assets acquired and the liabilities assumed exceeds the aggregate of the consideration transferred, non-controlling interest in the acquiree and fair value of the acquirer's previously held equity interest in the acquiree. [Refer: Total for all business combinations [member]]
Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities ifrs/2024 0 0 monetary D D Cash flows from losing control of subsidiaries or other businesses, classified as investing activities The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]
Investment Accounted For Using Equity Method ifrs/2024 0 0 monetary I D Investments accounted for using equity method The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]
Noncurrent Provisions ifrs/2024 0 0 monetary I C Non-current provisions The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]
Other Current Financial Assets ifrs/2024 0 0 monetary I D Other current financial assets The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]
Purchase Of Intangible Assets Classified As Investing Activities ifrs/2024 0 0 monetary D C Purchase of intangible assets, classified as investing activities The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]
Acquisition Of Short Term Investments 0001104659-25-035638 1 0 monetary D C Acquisition of short-term investments Acquisition of short-term investments
Income Tax Expense Continuing Operations ifrs/2024 0 0 monetary D D Tax expense (income) The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]
Noncurrent Liabilities ifrs/2024 0 0 monetary I C Non-current liabilities The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]
Assets ifrs/2024 0 0 monetary I D Assets The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.
Current Contract Assets ifrs/2024 0 0 monetary I D Current contract assets The amount of current contract assets. [Refer: Contract assets]
Diluted Earnings Loss Per Share ifrs/2024 0 0 perShare D Diluted earnings (loss) per share The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]
Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill ifrs/2024 0 0 monetary D Impairment loss recognised in profit or loss, intangible assets other than goodwill The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]
Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments ifrs/2024 0 0 monetary D C Other comprehensive income, before tax, gains (losses) from investments in equity instruments The amount of other comprehensive income, before tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income, before tax]
Other Finance Income ifrs/2024 0 0 monetary D C Other finance income The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]
Other Noncurrent Nonfinancial Assets ifrs/2024 0 0 monetary I D Other non-current non-financial assets The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]
Payments Of Lease Liabilities Classified As Financing Activities ifrs/2024 0 0 monetary D C Payments of lease liabilities, classified as financing activities The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]
Proceeds From Government Grants Classified As Investing Activities ifrs/2024 0 0 monetary D D Proceeds from government grants, classified as investing activities The cash inflow from government grants, classified as investing activities. [Refer: Government [member]; Government grants]
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities ifrs/2024 0 0 monetary D D Proceeds from sales of property, plant and equipment, classified as investing activities The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]
Research And Development Expense ifrs/2024 0 0 monetary D D Research and development expense The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.
Deferred And Current Tax On Future Deductible Expenses 0001104659-25-035638 1 0 monetary D C Deferred And Current Tax On Future Deductible Expenses Amount represents in deferred and current tax on future deductible expenses.
Proceeds From Divestment Sale Of Investments In Associated Companies Other Long Term Investments And Convertibles 0001104659-25-035638 1 0 monetary D D Proceeds from divestment/sale of investments in associated companies, other long-term investments and convertibles Proceeds from divestment/sale of investments in associated companies, other long-term investments and convertibles
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss ifrs/2024 0 0 monetary D D Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]
Adjustments For Income Tax Expense ifrs/2024 0 0 monetary D D Adjustments for income tax expense Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities ifrs/2024 0 0 monetary D C Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]
Interest Paid Classified As Financing Activities ifrs/2024 0 0 monetary D C Interest paid, classified as financing activities The cash outflow for interest paid, classified as financing activities.
Current Tax Assets Noncurrent ifrs/2024 0 0 monetary I D Current tax assets, non-current The non-current amount of current tax assets. [Refer: Current tax assets]
Share Issue Related Cost ifrs/2024 0 0 monetary D D Share issue related cost The amount of cost related to the issuance of shares.
Adjustments For Gain Loss On Disposal Of Investments In Subsidiaries Joint Ventures And Associates ifrs/2024 0 0 monetary D C Adjustments for gain (loss) on disposal of investments in subsidiaries, joint ventures and associates Adjustments for gain (loss) on disposals investments in subsidiaries, joint ventures and associates to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Total for all associates [member]; Total for all joint ventures [member]; Total for all subsidiaries [member]; Investments in subsidiaries, joint ventures and associates reported in separate financial statements; Profit (loss)]
Cash Flows From Used In Financing Activities ifrs/2024 0 0 monetary D D Cash flows from (used in) financing activities The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.
Expense Of Restructuring Activities ifrs/2024 0 0 monetary D D Expense of restructuring activities The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.
Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss ifrs/2024 0 0 monetary D D Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss The amount of income tax relating to amounts recognised in other comprehensive income that will not be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]
Net Deferred Tax Liabilities ifrs/2024 0 0 monetary I C Net deferred tax liabilities The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]
Noncurrent Assets ifrs/2024 0 0 monetary I D Non-current assets The amount of assets that do not meet the definition of current assets. [Refer: Current assets]
Noncurrent Deferred Income Other Than Noncurrent Contract Liabilities ifrs/2024 0 0 monetary I C Non-current deferred income other than non-current contract liabilities The amount of non-current deferred income other than non-current contract liabilities. [Refer: Deferred income other than contract liabilities]
Other Comprehensive Income Before Tax Financial Assets Measured At Fair Value Through Other Comprehensive Income ifrs/2024 0 0 monetary D C Other comprehensive income, before tax, financial assets measured at fair value through other comprehensive income The amount of other comprehensive income, before tax, after reclassification adjustments, related to financial assets measured at fair value through other comprehensive income applying paragraph 4.1.2A of IFRS 9. [Refer: Financial assets measured at fair value through other comprehensive income; Other comprehensive income]
Proceeds From Exercise Of Options ifrs/2024 0 0 monetary D D Proceeds from exercise of options The cash inflow from the exercise of options.
Profit Loss ifrs/2024 0 0 monetary D C Profit (loss) The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]
Weighted Average Shares ifrs/2024 0 0 shares D Weighted average number of ordinary shares used in calculating basic earnings per share The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.
Non Current Investments And Other Non Current Financial Assets 0001104659-25-035638 1 0 monetary I D Non-current investments and other non-current financial assets Non-current investments and other non-current financial assets
Proceeds From Sale Of Short Term Investment 0001104659-25-035638 1 0 monetary D D Proceeds from sale of short-term investments Proceeds from sale of short-term investments
Cash Flows From Used In Investing Activities ifrs/2024 0 0 monetary D D Cash flows from (used in) investing activities The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.
Cost Of Sales ifrs/2024 0 0 monetary D D Cost of sales The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.
Current Deferred Income Other Than Current Contract Liabilities ifrs/2024 0 0 monetary I C Current deferred income other than current contract liabilities The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]
Equity ifrs/2024 0 0 monetary I C Equity The amount of residual interest in the assets of the entity after deducting all its liabilities.
Intangible Assets And Goodwill ifrs/2024 0 0 monetary I D Intangible assets and goodwill The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]
Noncurrent Contract Liabilities ifrs/2024 0 0 monetary I C Non-current contract liabilities The amount of non-current contract liabilities. [Refer: Contract liabilities]
Noncurrent Financial Liabilities ifrs/2024 0 0 monetary I C Non-current financial liabilities The amount of non-current financial liabilities. [Refer: Financial liabilities]
Payments For Debt Issue Costs ifrs/2024 0 0 monetary D C Payments for debt issue costs The cash outflow for debt issue costs.
Selling General And Administrative Expense ifrs/2024 0 0 monetary D D Selling, general and administrative expense The amount of expense relating to selling, general and administrative activities of the entity.
Adjustments For Depreciation And Amortisation Expense ifrs/2024 0 0 monetary D D Adjustments for depreciation and amortisation expense Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]
Acquisition Of Investments In Associated Companies Other Long Term Investments And Convertibles 0001104659-25-035638 1 0 monetary D C Acquisition of investments in associated companies, other long-term investments and convertibles Acquisition of investments in associated companies, other long-term investments and convertibles
Adjustments For Finance Income Cost ifrs/2024 0 0 monetary D C Adjustments for finance income (cost) Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]
Current Assets ifrs/2024 0 0 monetary I D Current assets The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]
Current Restricted Cash And Cash Equivalents ifrs/2024 0 0 monetary I D Current restricted cash and cash equivalents The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]
Other Comprehensive Income Before Tax Gains Losses On Remeasurements Of Defined Benefit Plans ifrs/2024 0 0 monetary D C Other comprehensive income, before tax, gains (losses) on remeasurements of defined benefit plans The amount of other comprehensive income, before tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]
Proceeds From Borrowings Classified As Financing Activities ifrs/2024 0 0 monetary D D Proceeds from borrowings, classified as financing activities The cash inflow from borrowings obtained. [Refer: Borrowings]
Revenue ifrs/2024 0 0 monetary D C Revenue The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.
Adjustments For Share Of Result And Revaluation Of Investments Accounted For Using Equity Method 0001104659-25-035638 1 0 monetary D C Adjustments For Share Of Result And Revaluation of Investments Accounted For Using Equity Method Adjustments for share of result and revaluation of investments accounted for using equity method.
Additional Paidin Capital ifrs/2024 0 0 monetary I C Additional paid-in capital The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.
Basic Earnings Loss Per Share ifrs/2024 0 0 perShare D Basic earnings (loss) per share The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).
Current Provisions ifrs/2024 0 0 monetary I C Current provisions The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]
Income Taxes Refund Classified As Operating Activities ifrs/2024 0 0 monetary D D Income taxes refund, classified as operating activities The cash inflow from income taxes refunded, classified as operating activities.
Current Tax Assets Current ifrs/2024 0 0 monetary I D Current tax assets, current The current amount of current tax assets. [Refer: Current tax assets]
Current Tax Liabilities Current ifrs/2024 0 0 monetary I C Current tax liabilities, current The current amount of current tax liabilities. [Refer: Current tax liabilities]
Other Current Nonfinancial Liabilities ifrs/2024 0 0 monetary I C Other current non-financial liabilities The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]
Adjustments For Fair Value Gains Losses ifrs/2024 0 0 monetary D D Adjustments for fair value losses (gains) Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]
Trade And Other Current Receivables ifrs/2024 0 0 monetary I D Trade and other current receivables The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]
Share Of Profit Loss And Reevaluation Of Associates And Joint Ventures Accounted For Using Equity Method 0001104659-25-035638 1 0 monetary D C Share of profit (loss) and reevaluation of associates and joint ventures accounted for using equity method Share of profit (loss) and reevaluation of associates and joint ventures accounted for using equity method
Adjustments For Sharebased Payments ifrs/2024 0 0 monetary D D Adjustments for share-based payments Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]
Cash Flows From Used In Operating Activities ifrs/2024 0 0 monetary D Cash flows from (used in) operating activities The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]
Current Contract Liabilities ifrs/2024 0 0 monetary I C Current contract liabilities The amount of current contract liabilities. [Refer: Contract liabilities]
Gains Losses On Financial Assets At Fair Value Through Profit Or Loss ifrs/2024 0 0 monetary D C Gains (losses) on financial assets at fair value through profit or loss The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]
Income Taxes Paid Refund Classified As Operating Activities ifrs/2024 0 0 monetary D C Income taxes paid (refund), classified as operating activities The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]
Increase Decrease Through Exercise Of Options ifrs/2024 0 0 monetary D C Increase (decrease) through exercise of options, equity The increase (decrease) in equity resulting from the exercise of options.
Increase Decrease Through Sharebased Payment Transactions ifrs/2024 0 0 monetary D C Increase (decrease) through share-based payment transactions, equity The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]
Interest Received Classified As Investing Activities ifrs/2024 0 0 monetary D D Interest received, classified as investing activities The cash inflow from interest received, classified as investing activities.
Issued Capital ifrs/2024 0 0 monetary I C Issued capital The nominal value of capital issued.
Net Deferred Tax Assets ifrs/2024 0 0 monetary I D Net deferred tax assets The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]
Other Comprehensive Income ifrs/2024 0 0 monetary D C Other comprehensive income The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]
Total Operating Income And Expenses 0001104659-25-035638 1 0 monetary D C Total Operating Income And Expenses Amount of income related to nonoperating activities, classified as other.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001104659-25-035638 4 40 BS 0 H Noncurrent Liabilities ifrs/2024 Total non-current liabilities 0
0001104659-25-035638 4 42 BS 0 H Issued Capital ifrs/2024 Share capital 0
0001104659-25-035638 2 1 IS 0 H Revenue ifrs/2024 Revenue 0
0001104659-25-035638 2 2 IS 0 H Cost Of Sales ifrs/2024 Cost of Revenue 1
0001104659-25-035638 2 3 IS 0 H Gross Profit ifrs/2024 Gross profit 0
0001104659-25-035638 2 5 IS 0 H Research And Development Expense ifrs/2024 Research and development 1
0001104659-25-035638 2 6 IS 0 H Selling General And Administrative Expense ifrs/2024 Selling, general and administrative 1
0001104659-25-035638 2 7 IS 0 H Other Income ifrs/2024 Other operating income 0
0001104659-25-035638 2 8 IS 0 H Other Operating Expenses 0001104659-25-035638 Other operating expenses 1
0001104659-25-035638 2 9 IS 0 H Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill ifrs/2024 Impairments of intangible assets 1
0001104659-25-035638 2 10 IS 0 H Expense Of Restructuring Activities ifrs/2024 Reorganization costs 1
0001104659-25-035638 2 11 IS 0 H Total Operating Income And Expenses 0001104659-25-035638 Total operating income (expenses) 0
0001104659-25-035638 2 12 IS 0 H Profit Loss From Operating Activities ifrs/2024 Operating income (loss) 0
0001104659-25-035638 2 14 IS 0 H Gains Losses On Financial Assets At Fair Value Through Profit Or Loss ifrs/2024 Gain (loss) on investment in financial instruments reevaluation 0
0001104659-25-035638 2 15 IS 0 H Share Of Profit Loss And Reevaluation Of Associates And Joint Ventures Accounted For Using Equity Method 0001104659-25-035638 Share of profit (loss) and reevaluation of at-equity investments 0
0001104659-25-035638 2 16 IS 0 H Other Finance Income ifrs/2024 Other financial income 0
0001104659-25-035638 2 17 IS 0 H Other Finance Cost ifrs/2024 Other financial expense 1
0001104659-25-035638 2 18 IS 0 H Ifrs Other Non Operating Income Expense 0001104659-25-035638 Other non-operating income (expense) 0
0001104659-25-035638 2 19 IS 0 H Gain Recognised In Bargain Purchase Transaction ifrs/2024 Gain from Bargain Purchase 0
0001104659-25-035638 2 20 IS 0 H Profit Loss Before Tax ifrs/2024 Net Income (loss) before taxes 0
0001104659-25-035638 2 21 IS 0 H Income Tax Expense Continuing Operations ifrs/2024 Income taxes 1
0001104659-25-035638 2 22 IS 0 H Profit Loss ifrs/2024 Net income (loss) 0
0001104659-25-035638 2 23 IS 0 H Weighted Average Shares ifrs/2024 Weighted average shares outstanding 0
0001104659-25-035638 2 24 IS 0 H Basic Earnings Loss Per Share ifrs/2024 Net income per share (basic) 0
0001104659-25-035638 2 25 IS 0 H Diluted Earnings Loss Per Share ifrs/2024 Net income per share (diluted) 0
0001104659-25-035638 3 1 CI 0 H Profit Loss ifrs/2024 Net income (loss) 0
0001104659-25-035638 3 4 CI 0 H Other Comprehensive Income Before Tax Gains Losses On Remeasurements Of Defined Benefit Plans ifrs/2024 Remeasurement of defined benefit obligation 0
0001104659-25-035638 3 5 CI 0 H Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments ifrs/2024 Revaluation of equity investments 0
0001104659-25-035638 3 6 CI 0 H Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss ifrs/2024 Taxes 1
0001104659-25-035638 3 8 CI 0 H Other Comprehensive Income Before Tax Exchange Differences On Translation ifrs/2024 Foreign currency translation 0
0001104659-25-035638 3 9 CI 0 H Other Comprehensive Income Before Tax Financial Assets Measured At Fair Value Through Other Comprehensive Income ifrs/2024 Revaluation and disposal of other short-term investments 0
0001104659-25-035638 3 10 CI 0 H Income Tax Relating To Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss ifrs/2024 Taxes 1
0001104659-25-035638 3 11 CI 0 H Other Comprehensive Income ifrs/2024 Other comprehensive income (loss) 0
0001104659-25-035638 3 12 CI 0 H Comprehensive Income ifrs/2024 Total comprehensive income (loss) 0
0001104659-25-035638 4 3 BS 0 H Cash And Cash Equivalents ifrs/2024 Cash and cash equivalents 0
0001104659-25-035638 4 4 BS 0 H Current Investments ifrs/2024 Investments 0
0001104659-25-035638 4 5 BS 0 H Trade And Other Current Receivables ifrs/2024 Trade and other receivables 0
0001104659-25-035638 4 6 BS 0 H Current Contract Assets ifrs/2024 Contract assets 0
0001104659-25-035638 4 7 BS 0 H Inventories ifrs/2024 Inventories 0
0001104659-25-035638 4 8 BS 0 H Current Tax Assets Current ifrs/2024 Current tax assets 0
0001104659-25-035638 4 9 BS 0 H Other Current Financial Assets ifrs/2024 Other current financial assets including derivatives 0
0001104659-25-035638 4 10 BS 0 H Current Prepayments And Other Current Assets ifrs/2024 Prepaid expenses and other current assets 0
0001104659-25-035638 4 11 BS 0 H Current Assets ifrs/2024 Total current assets 0
0001104659-25-035638 4 13 BS 0 H Non Current Investments And Other Non Current Financial Assets 0001104659-25-035638 Non-current financial investments and other non-current financial assets 0
0001104659-25-035638 4 14 BS 0 H Investment Accounted For Using Equity Method ifrs/2024 Investments in associates and Joint ventures 0
0001104659-25-035638 4 15 BS 0 H Property Plant And Equipment Including Rightofuse Assets ifrs/2024 Property, plant and equipment 0
0001104659-25-035638 4 16 BS 0 H Intangible Assets And Goodwill ifrs/2024 Intangible assets and Goodwill 0
0001104659-25-035638 4 17 BS 0 H Net Deferred Tax Assets ifrs/2024 Deferred tax assets 0
0001104659-25-035638 4 18 BS 0 H Current Tax Assets Noncurrent ifrs/2024 Non-current tax assets 0
0001104659-25-035638 4 19 BS 0 H Other Noncurrent Nonfinancial Assets ifrs/2024 Other non-current assets 0
0001104659-25-035638 4 20 BS 0 H Noncurrent Assets ifrs/2024 Total non-current assets 0
0001104659-25-035638 4 21 BS 0 H Assets ifrs/2024 Total assets 0
0001104659-25-035638 4 25 BS 0 H Current Financial Liabilities ifrs/2024 Current financial liabilities 0
0001104659-25-035638 4 26 BS 0 H Trade And Other Current Payables ifrs/2024 Trade and other payables 0
0001104659-25-035638 4 27 BS 0 H Current Contract Liabilities ifrs/2024 Contract liabilities 0
0001104659-25-035638 4 28 BS 0 H Current Deferred Income Other Than Current Contract Liabilities ifrs/2024 Deferred income 0
0001104659-25-035638 4 29 BS 0 H Current Provisions ifrs/2024 Provisions 0
0001104659-25-035638 4 30 BS 0 H Current Tax Liabilities Current ifrs/2024 Current income tax liabilities 0
0001104659-25-035638 4 31 BS 0 H Other Current Nonfinancial Liabilities ifrs/2024 Other current liabilities 0
0001104659-25-035638 4 32 BS 0 H Current Liabilities ifrs/2024 Total current liabilities 0
0001104659-25-035638 4 34 BS 0 H Noncurrent Financial Liabilities ifrs/2024 Non-current financial liabilities 0
0001104659-25-035638 4 35 BS 0 H Net Deferred Tax Liabilities ifrs/2024 Deferred tax liabilities 0
0001104659-25-035638 4 36 BS 0 H Noncurrent Provisions ifrs/2024 Provisions 0
0001104659-25-035638 4 37 BS 0 H Noncurrent Contract Liabilities ifrs/2024 Contract liabilities 0
0001104659-25-035638 4 38 BS 0 H Noncurrent Deferred Income Other Than Noncurrent Contract Liabilities ifrs/2024 Deferred income 0
0001104659-25-035638 4 39 BS 0 H Other Noncurrent Nonfinancial Liabilities ifrs/2024 Other non-current liabilities 0
0001104659-25-035638 4 43 BS 0 H Additional Paidin Capital ifrs/2024 Additional paid in capital 0
0001104659-25-035638 4 44 BS 0 H Retained Earnings ifrs/2024 Retained Earnings 0
0001104659-25-035638 4 45 BS 0 H Accumulated Other Comprehensive Income ifrs/2024 Accumulated other comprehensive income 0
0001104659-25-035638 4 46 BS 0 H Equity ifrs/2024 Total stockholders' equity 0
0001104659-25-035638 4 47 BS 0 H Equity And Liabilities ifrs/2024 Total liabilities and stockholders' equity 0
0001104659-25-035638 5 2 CF 0 H Profit Loss ifrs/2024 Net income (loss) 0
0001104659-25-035638 5 3 CF 0 H Adjustments For Income Tax Expense ifrs/2024 Income tax expense 0
0001104659-25-035638 5 4 CF 0 H Adjustments For Depreciation And Amortisation Expense ifrs/2024 Depreciation and amortization 0
0001104659-25-035638 5 5 CF 0 H Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss ifrs/2024 Impairment of tangible and intangible assets 0
0001104659-25-035638 5 6 CF 0 H Adjustments For Sharebased Payments ifrs/2024 Equity settled share based payment transaction 0
0001104659-25-035638 5 7 CF 0 H Adjustments For Finance Income Cost ifrs/2024 Financial income and expenses 1
0001104659-25-035638 5 8 CF 0 H Adjustments For Share Of Result And Revaluation Of Investments Accounted For Using Equity Method 0001104659-25-035638 Share of loss (profit) and reevaluation of at-equity investments 1
0001104659-25-035638 5 9 CF 0 H Adjustments For Fair Value Gains Losses ifrs/2024 Gain (loss) on investment in financial instruments reevaluation 0
0001104659-25-035638 5 10 CF 0 H Adjustments For Transactions Costs And Income Related To Acquisitions 0001104659-25-035638 Transactions costs and income related to acquisitions 1
0001104659-25-035638 5 11 CF 0 H Other Adjustments For Noncash Items ifrs/2024 Other non-cash items 0
0001104659-25-035638 5 12 CF 0 H Adjustments For Gain Loss On Disposal Of Investments In Subsidiaries Joint Ventures And Associates ifrs/2024 Loss on sale of investment of affiliated companies 1
0001104659-25-035638 5 13 CF 0 H Increase Decrease In Working Capital ifrs/2024 Changes in net working capital 1
0001104659-25-035638 5 14 CF 0 H Income Taxes Paid Refund Classified As Operating Activities ifrs/2024 Taxes paid, net of refunds 1
0001104659-25-035638 5 15 CF 0 H Cash Flows From Used In Operating Activities ifrs/2024 Net cash from operating activities 0
0001104659-25-035638 5 17 CF 0 H Interest Received Classified As Investing Activities ifrs/2024 Interest received 0
0001104659-25-035638 5 18 CF 0 H Purchase Of Property Plant And Equipment Classified As Investing Activities ifrs/2024 Purchase of property, plant and equipment 1
0001104659-25-035638 5 19 CF 0 H Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities ifrs/2024 Proceeds from sale of property, plant and equipment 0
0001104659-25-035638 5 20 CF 0 H Purchase Of Intangible Assets Classified As Investing Activities ifrs/2024 Purchase of intangible assets and capitalization of development expenditures 1
0001104659-25-035638 5 21 CF 0 H Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities ifrs/2024 Acquisition of subsidiaries net of cash acquired 1
0001104659-25-035638 5 22 CF 0 H Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities ifrs/2024 Divestment of affiliated companies, net of cash disposed 0
0001104659-25-035638 5 23 CF 0 H Acquisition Of Investments In Associated Companies Other Long Term Investments And Convertibles 0001104659-25-035638 Purchase of investments in associated companies, other non-current investments and convertibles 1
0001104659-25-035638 5 24 CF 0 H Proceeds From Divestment Sale Of Investments In Associated Companies Other Long Term Investments And Convertibles 0001104659-25-035638 Proceeds from divestment /sale of investments in associated companies, other non-current investments and convertibles 0
0001104659-25-035638 5 25 CF 0 H Acquisition Of Short Term Investments 0001104659-25-035638 Purchase of current investments 1
0001104659-25-035638 5 26 CF 0 H Proceeds From Sale Of Short Term Investment 0001104659-25-035638 Proceeds from sale of current investments 0
0001104659-25-035638 5 27 CF 0 H Proceeds From Government Grants Classified As Investing Activities ifrs/2024 Proceeds from government grants 0
0001104659-25-035638 5 28 CF 0 H Cash Flows From Used In Investing Activities ifrs/2024 Net cash used in investing activities 0
0001104659-25-035638 5 30 CF 0 H Interest Paid Classified As Financing Activities ifrs/2024 Interest paid 1
0001104659-25-035638 5 31 CF 0 H Proceeds From Issuing Shares ifrs/2024 Proceeds from capital increase 0
0001104659-25-035638 5 32 CF 0 H Proceeds From Borrowings Classified As Financing Activities ifrs/2024 Proceeds from loans 0
0001104659-25-035638 5 33 CF 0 H Payments For Debt Issue Costs ifrs/2024 Transaction costs related to loans 1
0001104659-25-035638 5 34 CF 0 H Proceeds From Exercise Of Options ifrs/2024 Proceeds from the exercise of share options 0
0001104659-25-035638 5 35 CF 0 H Repayments Of Borrowings Classified As Financing Activities ifrs/2024 Repayments of loans 1
0001104659-25-035638 5 36 CF 0 H Payments Of Lease Liabilities Classified As Financing Activities ifrs/2024 Repayments of lease liabilities 1
0001104659-25-035638 5 37 CF 0 H Cash Flows From Used In Financing Activities ifrs/2024 Net cash from financing activities 0
0001104659-25-035638 5 38 CF 0 H Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes ifrs/2024 Net increase (decrease) in cash equivalents 0
0001104659-25-035638 5 39 CF 0 H Cash And Cash Equivalents ifrs/2024 Cash and cash equivalents at January 1 0
0001104659-25-035638 5 40 CF 0 H Effect Of Exchange Rate Changes On Cash And Cash Equivalents ifrs/2024 Effects of revaluation and of movements in exchange rates on cash held 0
0001104659-25-035638 5 41 CF 0 H Cash And Cash Equivalents ifrs/2024 Cash and cash equivalents at December 31 0
0001104659-25-035638 6 1 CF 1 H Current Restricted Cash And Cash Equivalents ifrs/2024 Restricted cash 0
0001104659-25-035638 6 2 CF 1 H Income Taxes Refund Classified As Operating Activities ifrs/2024 R&D tax credits received 0
0001104659-25-035638 7 10 EQ 0 H Equity ifrs/2024 Beginning balance 0
0001104659-25-035638 7 11 EQ 0 H Number Of Shares Issued ifrs/2024 Beginning balance (Shares) 0
0001104659-25-035638 7 12 EQ 0 H Increase Decrease Through Exercise Of Options ifrs/2024 Exercised stock options 0
0001104659-25-035638 7 13 EQ 0 H Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period 0001104659-25-035638 Exercised stock options (shares) 0
0001104659-25-035638 7 14 EQ 0 H Increase Decrease Through Sharebased Payment Transactions ifrs/2024 Stock option plan 0
0001104659-25-035638 7 15 EQ 0 H Share Issue Related Cost ifrs/2024 Transaction costs 1
0001104659-25-035638 7 16 EQ 0 H Deferred And Current Tax On Future Deductible Expenses 0001104659-25-035638 Deferred and current tax on future deductible expenses 0
0001104659-25-035638 7 17 EQ 0 H Other Comprehensive Income ifrs/2024 Other comprehensive income 0
0001104659-25-035638 7 18 EQ 0 H Profit Loss ifrs/2024 Net income (loss) for the period 0
0001104659-25-035638 7 19 EQ 0 H Comprehensive Income ifrs/2024 Total comprehensive income (loss) 0
0001104659-25-035638 7 20 EQ 0 H Equity ifrs/2024 Ending balance 0
0001104659-25-035638 7 21 EQ 0 H Number Of Shares Issued ifrs/2024 Ending balance (Shares) 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.